REG - GSK PLC - GSK Cervarix two-dose schedule approved by NMPA

GSKAnnouncement

27/05/2022 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220527:nRSa9809Ma&default-theme=true

RNS Number : 9809M  GSK PLC  27 May 2022

Issued: 27 May 2022, London UK

 

China approves Cervarix two-dose vaccine schedule for girls aged 9 to 14
against certain types of cancer-causing human papillomavirus

 

·   China's National Medical Products Administration (NMPA) has approved a
two-dose vaccine schedule for Cervarix in girls aged between 9 to 14 years for
the prevention of cervical cancer, cervical intraepithelial neoplasia and
adenocarcinoma in situ causally related to oncogenic Human Papillomavirus
(HPV) types 16 and 18

·   In 2020, there were approximately 110,000 new cases of cervical cancer
and 59,000 deaths due to the disease in China(1)

 

GSK plc (LSE/NYSE: GSK) announced today that a two-dose schedule for its HPV
vaccine Cervarix [Human Papillomavirus bivalent (types 16, 18) Vaccine,
Recombinant)] has been approved by China's NMPA for girls aged 9 to 14. With
this approval, Cervarix is the first imported two-dose HPV vaccine for this
age group in mainland China.

 

The NMPA authorisation of the two-dose regimen adds China to two-dose
approvals in approximately 100 countries, including the European Union, Asia,
Africa, and Latin America(2-7). The three-dose schedule remains on the label
for girls and women aged 15-45 years in China.

 

About cervical cancer

Cervical cancer has the highest mortality of all malignant tumours in the
female reproductive system in China(1), with 110,000 new cases of cervical
cancer and 59,000 deaths due to the disease. Incidence and mortality rates
show an increasing trend in younger women(8). The potential impact of vaccines
against oncogenic HPV types 16 and 18 is estimated to be high (84.5%) against
total squamous cell carcinoma (SCC).(9)

 

Vaccination with HPV vaccine in the female population at appropriate ages may
significantly reduce the morbidity of cervical cancer and precancerous
lesions, thereby reducing the burden of the disease. HPV is predominately
transmitted through sexual contact; the primary target population for HPV
vaccination is girls aged 9-14 years who have not yet had sex. With a two-dose
schedule, more girls could be vaccinated against HPV, leading to the
protection of more women against HPV-related cervical cancer.

 

About Cervarix

Cervarix (Human Papillomavirus vaccine Types 16 and 18 [Recombinant, AS04
adjuvanted]) is a non-infectious recombinant, AS04-adjuvanted vaccine.
Cervarix demonstrated direct evidence of lowering cervical cancer incidence
rates(10). A register-based study in England where girls were offered the
vaccine in school year eight (aged 12 to 13 years), had an 87% reduction for
cervical cancer and 97% reduction for precancerous lesions (cervical
intraepithelial neoplasia, CIN, grade 3); a more significant effect than
expected based on the incidence of HPV 16/18 strains (68%) included in the
vaccine(10). Cervarix has also shown to be effective 93·2% (78·9-98·7)
against all CIN3+, irrespective of HPV type in the lesion and including
lesions with no HPV 16/18 DNA detected, suggesting a wider than HPV 16/18
benefit.(11)

 

 

 

About GSK

GSK is a science-led global healthcare company. For further information,
please visit www.gsk.com/about-us (https://www.gsk.com/en-gb/about-us/) .

 

 

 

 GSK enquiries:
 Media enquiries:             Tim Foley        +44 (0) 20 8047 5502  (London)
                              Simon Moore      +44 (0) 20 8047 5502  (London)
                              Kathleen Quinn   +1 202 603 5003       (Washington DC)
                              Lyndsay Meyer    +1 202 302 4595       (Washington DC)

 Analyst/Investor enquiries:  Nick Stone       +44 (0) 7717 618834   (London)
                              Sonya Ghobrial   +44 (0) 7392 784784   (Consumer)
                              James Dodwell    +44 (0) 20 8047 2406  (London)
                              Mick Readey      +44 (0) 7990 339653   (London)
                              Josh Williams    +44 (0) 7385 415719   (London)
                              Jeff McLaughlin  +1 215 751 7002       (Philadelphia)

 

Cautionary statement regarding forward-looking statements

GSK cautions investors that any forward-looking statements or projections made
by GSK, including those made in this announcement, are subject to risks and
uncertainties that may cause actual results to differ materially from those
projected. Such factors include, but are not limited to, those described in
the Company's Annual Report on Form 20-F for 2021, GSK's Q1 Results for 2022
and any impacts of the COVID-19 pandemic.

 

Registered in England & Wales:

No. 3888792

 

Registered Office:

980 Great West Road

Brentford, Middlesex

TW8 9GS

 

Reference:

1.     Chen WQ, Zheng RS, Baade PD,et al. Cancer Statistics in China,
2015. CA CANCER J CLIN 2016; 00:00-00:1-18

2.     GSK. GSK Cervarix(®) two-dose schedule receives European marketing
authorisation
https://www.gsk.com/en-gb/media/press-releases/gsk-cervarix-two-dose-schedule-receives-european-marketing-authorisation/

3.     Lyseng-Williamson, K.A., Human papillomavirus-16/18 AS04-adjuvanted
vaccine (Cervarix®): a guide to its two-dose schedule in girls aged 9-14
years in the EU. Paediatr Drugs, 2014. 16(3): p. 247-53.

4.     Tay, S.K., et al., Cost-effectiveness of two-dose human
papillomavirus vaccination in Singapore. Singapore Med J, 2018. 59(7): p.
370-382.

5.     Germar, M.J., et al., Cost-effectiveness analysis of
AS04-adjuvanted human papillomavirus 16/18 vaccine compared with human
papillomavirus 6/11/16/18 vaccine in the Philippines, with the new 2-dose
schedule. Hum Vaccin Immunother, 2017. 13(5): p. 1158-1166.

6.     Van Kriekinge, G., et al., Comparative Cost-Effectiveness Analysis
of Two Different Two-Dose Human Papillomavirus Vaccines in Malaysia. Asian Pac
J Cancer Prev, 2018. 19(4): p. 933-940.

7.     GSK. GSK internal tracking system for Global Regulatory Affairs.

8.     Liuye Huang, Xuelian Zhao,Fanghui Zhao.Trends in incidence and
mortality of cervical cancer and progress in its prevention strategies J .
Electronic Journal of Comprehensive Cancer Therapy, 2021

9.     Chen, W., et al., Human papillomavirus type-distribution in
cervical cancer in China: the importance of HPV 16 and 18. Cancer Causes
Control, 2009. 20(9): p. 1705-13.

10.    Falcaro M, Castañon A, Ndlela B, Checchi M, Soldan K, Lopez-Bernal
J, Elliss-Brookes L, Sasieni P. The effects of the national HPV vaccination
programme in England, UK, on cervical cancer and grade 3 cervical
intraepithelial neoplasia incidence: a register-based observational study.
Lancet. 2021 Nov 3:S0140-6736(21)02178-4.

11.    Lehtinen M, Paavonen J, Wheeler CM, et al. Overall efficacy of HPV
16/18 AS04-adjuvanted vaccine against grade 3 or greater cervical
intraepithelial neoplasia: 4-year end-of-study analysis of the randomised,
double-blind PATRICIA trial - Web appendix. Lancet Oncol 2012; 13: 89-99.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCFLFIEEEIRFIF